# TROP2 expression

Source: https://onco.cc/biomarkers/trop2-expression/  
OnCo record `trop2-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TROP2 is on the surface of most breast and lung cancers. Sacituzumab govitecan and datopotamab deruxtecan are given without measuring it; a computational TROP2 score is being tested as a selector in lung cancer.

## Summary

Sacituzumab govitecan (Trodelvy) is labelled for triple-negative and HR-positive HER2-negative breast cancer and urothelial cancer, datopotamab deruxtecan (Datroway) for HR-positive HER2-negative breast cancer and EGFR-mutant NSCLC, in both cases without a TROP2 test. The TROPION-Lung01 exploratory analysis introduced a quantitative continuous scoring (normalised membrane ratio) that separated responders in non-squamous NSCLC; it is being validated prospectively (TROPION-Lung12, NCT06564844 and other studies) and is not in any label.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: TROP2; TROP-2; Trop-2 expression; TACSTD2 expression; TROP2 QCS; TROP2 normalised membrane ratio
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- TRODELVY prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d

## Connected records

- terms: [HER2-low and HER2-ultralow](https://onco.cc/terms/her2-low/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/)
- biomarkers: [CEACAM5 expression](https://onco.cc/biomarkers/ceacam5-expression/), [Nectin-4 expression](https://onco.cc/biomarkers/nectin-4-expression/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/trop2-expression.json